The rationale of this trial is to directly target the tumor with the anti-MUC1 mAb, while unspecifically stimulate the immune response with beta glucan by binding to an alternate site on the neutrophil complement receptor 3 (CR3), priming the neutrophil to become cytotoxic after binding to complement on tumor cells via CR3. This evidence concerns the gene CRIPTO3 and neoplasm.